Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

AllPaths Podcast

AllPaths Podcast artwork

The 46 Books on the Shelf

Nov 3, 202640 minAudio
ShareXLinkedInFacebookWhatsAppEmail

You did the retrieval, waited anxiously for the results, and received the news that your embryo is chromosomally normal and ‘healthy.’ So why didn’t it become a successful pregnancy? This heartbreaking paradox is one of the most confusing hurdles in modern fertility treatment. When patients undergo standard pre-implantation genetic testing (PGT-A), they often assume an embryo labeled "normal" guarantees a healthy pregnancy. Yet, as today’s guest explains, even fully tested euploid embryos fail to result in a live birth 40% to 50% of the time. Jeremy Grushcow, founder and CEO of Juniper Genomics, shares the limitations of standard pre-implantation genetic testing, how Juniper is helping families get deeper genomic clarity, and howPGT-A acts like a quick headcount of chromosomes, confirming whether all 46 "books" are present on the shelf, but it never opens those books to read the genetic text inside. Even with all 46 chromosomes in place, hidden sequence-level "typos" or more technically, reduced viability variants within vital developmental genes, can quietly halt an embryo's growth. Jeremy’s dedication to this field is deeply personal: during his PhD in molecular genetics, his family tragically lost a young relative to a sudden cardiac event caused by an undetected single-gene disorder. That loss illuminated the life-saving importance of identifying hidden risks early and stayed with him through careers in law and population genetics. When a clinician later challenged him on why he would "medicalize" pregnancy, Jeremy was galvanized to act. Embryos can be screened for monogenic conditions through PGT-M, but that requires families knowing that they’re at an increased risk of passing on a specific condition at the start. Through PGT-G testing, Juniper takes the books off the shelf, opens them up, and reads the actual letters across all 3 billion base pairs of DNA to detect reduced viability variants that contribute to unexplained pregnancy loss and implantation failures. And while sequencing embryos through PGT-G is at the core of Juniper Genomics' mission, their work extends well beyond the embryo stage. Recognizing that embryo quality is only one part of the fertility equation, they tackle unexplained transfer failures and pregnancy loss from multiple angles including parental blood testing, RNA transcriptome data, and more so that families, clinicians, and payers can choose confidence over uncertainty at every step. Learn more at https://www.junipergenomics.com/. TOPICS COVERED IN THIS EPISODE: PGT-G, Pre-implantation Genetic Testing for Genomics, PGT-A, Pre-implantation Genetic Testing for Aneuploidy, Whole-Genome Sequencing, Transcriptome / RNA Sequencing, Euploid Embryos, Reduced Viability Variants, Single-Gene Disorders, Genetic "Typos", Carrier Screening, Jeremy Grushcow, Juniper Genomics, Juniper Insight (Parental Blood Panel), Euploid (Meiosis Medication), Evie (Vaginal Microbiome), Stem-Cell-Derived Gametes, In Vitro Fertilization (IVF), Embryo Transfer Failure, Recurrent Implantation Failure (RIF), Paternal Age & Sperm Genetics, Gamete Quality, Sperm Freezing, Surrogacy & Donor Gametes, Removing Patient Self-Blame, IVF Economics & Payer Alignment, Healthcare Efficiency CONNECT WITH ALLPATHS FAMILY BUILDING: https://allpathsfb.org Follow us on social media @allpathsfb Want to share your story or ask a question? Get in touch at podcast@allpathsfb.org!

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

Building a family can be a complicated, messy, lonely, and sometimes heartbreaking process. But you don't have to navigate this challenging journey alone. Welcome to the AllPaths podcast, where we support and celebrate all of the different ways there are to try to grow your family. We're your hosts, Emily and Liane, from the nonprofit organization AllPaths Family Building. And today we're talking with Jeremy Grushcow, the CEO of Juniper Genomics,

about his work in this space. Jeremy, thank you so much for joining us today. Thanks so much for having me. So, before we dive in, we'd love for you just to quickly introduce yourself to our listeners. Sure. I'm Jeremy Grushko. I am the founder and CEO at Juniper Genomics. I started my career in the lab. I did my PhD in molecular genetics and cell biology at University of Chicago. I didn't know it at the time, but it was some real foreshadowing. I was working on meiosis

and DNA repair and recombination, and I was at the time interested in that from the point of view of the biology and the genetics, which was super interesting. And it's turned out, of course, to be super relevant to what we do today at Juniper in helping people succeed in ivf. Great. Thank you for that. Well, let's just jump right in. Can you tell us a little bit more about your own journey and how did you get into this fertility field? Yeah, so I definitely came to it from the genetic side, from the

time of my PhD around the same time, unfortunately, we lost a family member to a sudden cardiac event at a young age. And the more we learned about genetics as a field, the more we know that those events are often single gene disorders called channelopathies. And so as the human genome was sequenced, I actually wrote some blog posts in 2008, 2009, saying that I think this, you know, the intersection of genetics and IVF could be really important

for families like ours. You know, what at the time was pgtm? The ability to detect and avoid monogenic disease. But many families don't know that they carry that risk. And the ability to look at it and think about it more broadly seemed really important to me. So it's always been on my mind. And then as my career transitioned from genetics to law and startups and actually into the operating world in startups, I started working on population genetics. I

worked with folks who were part of the Human Genome Project and part of the all of Us Project and part of the clinical implementation of genetics in the NICU and in the health systems. I think that this was always in the back of my mind and the ability to bring genetics into the IVF process was on my mind. And then I talked to a clinician when I was starting Juniper and thinking about genetic disease. And that clinician started talking to me about pregnancy loss. And he said, it's not just IVF where

this is a challenge, that even pregnancy is conceived without medical assistance and in loss 25, 30% of the time. And, you know, immediately I thought about how much of early development we can address for kids in the, in the intensive care unit and how often that's a genetic cause. And that, oh, you know, even earlier must be even more genetic cause. There's less environment, there's more genetics. It must be like something that we could really do something about. And then he said, well, why would you medicalize pregnancy? And well, that's ridiculous, right? First of all,

there's no other encounter where if you had a 25 or 30% rate of adverse events that resulted in medical risk and tragedy and heartbreak, that we would ignore it the way we do for pregnancy loss. And second of all, IVF has already medicalized pregnancy. Why wouldn't we just do it as well as we possibly can and create the highest success rates and the fastest, most confident journeys we possibly can? And so that was really galvanizing for me when I said, actually, I think that the way that I came to this is not the experience that people are having when they're in ivf. And we

could really address the central problem of ivf, which is that today you can have a fully tested embryo and there's a 40 to 50% chance that that embryo is not going to result in a live birth. Yeah, I think that's a really important point to talk about a little bit more for people who are listening, who might not understand what you meant by that. So talk a little bit more about what is typically done and that 40% chance and then what's a little bit different in the way you're testing and thinking about at Brios.

So, you know, right now, in modern ivf, almost every cycle is what we call a freeze all cycle, where we're, you know, retrieving a number of eggs. Some fraction of those eggs get fertilized successfully. Some fraction of those fertilized eggs grow to the day five to seven stage. They become what we call a blastocyst with about 200 cells in a sphere. The outside of that sphere becomes the placenta called the trophectoderm. The inside of that sphere called the inner Cell mass becomes the embryo and

the fetus. And when you get to that blastocyst stage right now, one of two things happen. Either you freeze that blastocyst or three things, I guess you can transfer that blastocyst in a fresh cycle one, and then you freeze the rest, or you can freeze all of them and transfer them in subsequent cycles. We typically transfer embryos one at a time, which is relatively new in IVF. Right. Over the last 10 years, we shift towards transferring one embryo at a time. But that opportunity to choose one embryo at a time and the necessity for pregnancy success and safety of transferring one embryo at a time means that choosing that embryo

becomes really important. And so there's two ways today that we choose an embryo right. Way number one is what we call kind of a beauty contest, the embryo morphology or grade, which one is the roundest and prettiest embryo. And that's okay, you know, it's better than choosing at random. But if you're choosing an embryo based on morphology alone, on average, you can expect about a 35% chance that that embryo is going to result in a live birth, which means a 65% chance that that embryo is not going

to result in a live birth. And the second thing that we can do to choose an embryo today is pgt a pre implantation genetic testing for aneuploidy. And that's where, if you think about the genome of the embryo as a set of books on a shelf, we all have 46 chromosomes. Those 46 chromosomes are like 46 books on a shelf. PGT A checks to make sure that the embryo has 46 chromosomes. Because we know that almost all the time, if you have 47 or 45

or a different number than 46, that embryo is not going to succeed. So through pregnancy. So that's what we do with pgta. Are all the books the right number of books on the shelf? Right. And by doing that, we avoid transferring embryos that have the wrong number of books. So we avoid some of those failures. And when you do use a PGT, a tested embryo, those on average have a 55% chance of resulting in a live birth. But that still means that there's a 45% chance that you've done all the steps, you've

gotten a number of embryos, you've tested those embryos. With pgta, it's a euploid embryo, and those embryos still don't make it to live birth 45% of the time. Yeah. And that's really hard reality for a lot of people. In our community, I mean, we hear that often in our loss groups that, you know, how did this happen? This was tested in a little bit deeper, dive into, like, what the tests are actually looking for. And that piece is not always understood by folks. They just assume, like, oh, it was tested. It's a quote unquote good embryo,.

Right? And we see this in genetics all the time and in IVF all the time. And it's not the patient's fault and it's not the doctor's fault, right? This is such a complicated set of procedures. There's so many conversations. And even really knowledgeable doctors and really knowledgeable patients are not able to, you know, think through, work through, educate themselves fully about all of the different tests and contingencies along this path. I think, you know, we talk to our friends, we, you know, trust our clinicians. I think all those things are appropriate. We do the research. They. But still, like, genetics is complicated,

right? When we talk about PGT A even, which is just like checking the books on a shelf, right? That seems so straightforward. But how do we talk about that, right? What we're actually doing is not so much choosing an embryo with the right number of books, we're actually avoiding the embryos with the wrong number of books. Like genetics is built in all these double negatives, right? We're deselecting non viable embryos, which is a mouthful and confusing. And so often when people talk about this, they say,

oh, the embryos with the right number of books on the shelf, the embryo with the right number of chromosomes, PGT A tested embryos, euploid embryos. What's a great shorthand for that? Healthy embryos. Yeah,. Right? So tons of people say healthy embryos. And then when you transfer to healthy embryo and it doesn't succeed, what happened? Well, now we're having a different conversation because that healthy is such an extraordinary shorthand, right? There's actually no other area of medicine where we use genetics and

we stop at looking at the books on a shelf, right? If you, God forbid, if your kid is in the NICU or you have a kid with a developmental disorder and you're getting sequencing, or you have cancer, or you have a history of genetic disease in your family, or even carrier screening, that is not a books on a shelf test, that's a sequencing test. We're opening up those books and we're reading the letters inside those books, right? To look for typos that cause genetic disease or disorders. And

we have not been doing that in IVF until very, very recently. Not because we didn't care about it, but because the technology was not available. When we're looking at that blastocyst, where we have a few hundred cells in a ball, what we take from that to understand the embryo is just a few cells from the outside of the trophectoderm part becomes the placenta. That embryo biopsy is only typically three to eight cells. And that's not historically been enough to look inside the books and read the letters. So one

of the innovations really, over the last five years that Juniper and some other companies are starting to use is that technology to allow us to amplify that DNA with sufficient accuracy to be able to read the letters, inside the books, inside the chromosomes, to read all of those 3 billion base pairs that make up the genome of human being, and at a level of clinical accuracy that allows us to make some judgments about what might be going on in those chromosomally normal euploid embryos that currently do not succeed

in reaching live birth. With Juniper PGTG for genomics, we're taking all of those books off the shelf and we're reading every single letter to say, is there a typo in one of the genes on one of your chromosomes that could be causing an embryo to fail? We call those reduced viability variants because they're variants that are impacting genes that might be necessary for the successful development of an embryo. And there's, you know, in your whole genome, there's about 20, 25,000 genes. Over 10,000 of those

we know have some role between being a fertilized egg and a living human. And if one of those genes gets disrupted, it can explain why a specific embryo is failing. You know, we had one family that we worked with where they had had a child, but then after that they had several years of infertility, they had several failed cycles. We met them when they were starting a new cycle. They made six embryos. Five of those embryos were Euploid Chrome's, only normal PGTA tested. And those five embryos had the same morphology.

They were the same day, the same grade, indistinguishable by any current technology. And when we did PGTG testing on them, when we looked at inside all those books for typos, we found that four of those five embryos actually had reduced viability variants. We were able to transfer the fifth embryo that didn't have those variants. That embryo is now an ongoing pregnancy in the third trimester for the first time in years. So there really is a connection between what we're Looking for with these variants and the outcomes of individual embryo transfers where without that data, you know,

they could have had four more failed embryo transfers before they found that embryo. And I think, you know, the experience of that at a certain point just becomes unbearable. And we really would like to be able to provide that data to people as early as possible in their journey. Yeah. So that's what we're doing with pgtg. That's incredible. So is this, I guess, the ideal use case for folks who are already doing IVF for genetic testing purposes, whether it's because of something in their family history, their personal history, a past pregnancy or birth, or is this ideal use case

going to be to, you know, make this available for everybody so, you know, maybe you don't have to have that, like, tragic backstory to qualify to do this sort of genetic testing? Yeah, I mean, I think that's, you know, like a lot of pieces of ivf, Right. How much testing you want to do, how deep a dive you want to do, is really a pretty individual choice in terms of where people are at in their journey. But when you think about it in terms of the numbers of how IVF works, right. When you think about right now without this data, there's almost a 50, 50 chance whether an embryo succeeds or fails after a transfer. I really

think this is for everybody, because failed transfers are not free or easy. Right there. They're, you know, on average, a frozen Embryo transfer costs $5,000 between the procedure costs and the medication costs. Right. And in addition to that, you know, failed transfers can fail at the pregnancy test phase. They can fill at a later phase about, you know, 10 to 20% of the time. They require, you know, an active medical termination of

the pregnancy, which is horrendous and not without medical risk. And when you look at what patients do today, when that happens, there's a lot of additional challenges, right? If you have a failed transfer where you've done everything that was asked of you and the transfer still fails, what do you do next today? First of all, what almost every patient does today

is blames themselves. Because that's the narrative, right? A pregnancy failed, it must be the fault of the person with the uterus who failed to carry a pregnancy, who miscarried a pregnancy. Right. You know, we look for these things, but we know that that's actually not the case. Right. If you have five euploid embryos to transfer, 98% of women will succeed in carrying a pregnancy to a live birth across those five embryo transfers. Right. Unless they have

some Other existing diagnosis. So if you like. So if you haven't been diagnosed and a transfer fails, the likelihood that there's something going on with you that caused that failure is very, very low. Like, I would say, 2% or less. But unless you can say what it is, knowing what it's not doesn't help that much. Right. And so people do all kinds of things. They, they look into their diet, they look into their exercise, they look into their vitamins, they look into their immune system, they look into. They look

into a lot of things. They don't often look into their partners, even though older men contribute half of the risk to older embryos. So there's a lot of places that people look right now in the absence of data about what's wrong with the embryo itself. And so many doctors, if they have that conversation, will say, listen, this is not about you. There's something in the embryo that we weren't able to determine that caused this embryo to fail. And so Juniper with PGTG for Genomics is looking at all of those 3 billion letters and saying, can we find that explanation for

people so that they can understand maybe why that embryo failed and identify more importantly an embryo the first time that's more likely to succeed so that you don't have to ask yourself those questions, so that you don't have to say, oh, I only have two EUPLATE embryos left. Maybe I should be using a surrogate. Maybe I need to consider an egg donor. The long, complicated paths that people take when a few EUPLATE transfers don't succeed, where maybe that successful embryo is sitting there in the freezer

already. And it's just, you know, it's really scary to use your last couple of embryos without knowing that you've been able to do something different. Yeah. And I also think a lot of people in that scenario that you just described, where you may have gone through a few losses of what you thought were, you know, PGA tested, normal embryos will often be counseled to maybe do another round of retrieval because, you know, you're still. Your time is of the essence. Let's get as many as eggs as we can when you're younger. And that

invites a whole nother cycle of cost and time, you know, and procedures that perhaps could have been avoided. So I think there's a lot of things to be thinking about here when we're talking about the statistics and the cost and the procedure, the heartache, the delay to pregnancy time. Right. And right now, patients and doctors are having those conversations based on statistics and we know that statistics are not necessarily

going to help with a person's individual journey. There was a patient I talked to whose doctor did not routinely recommend PGT A for patients in her age group and in fact counseled pretty heavily against her using PGTA. And even though she was under 35, turned out that 75% of her embryos were not crumbs, only normal, which is super unusual for that age group, but not that unusual in the realm of statistics. Right. It's way different than the average, but it's not that unlikely. So I think what your individual journey

looks like, what your individual risk looks like, what your specific embryos look like, is not necessarily the wrong decision to do another cycle. But if you're making that decision based on averages, it's not telling you really very much about those specific embryos and your specific risk. And that's really what we've tried to give people much, much better data about at Juniper. That's. That's an interesting case study, too, because I feel like a lot of us end up being that patient where they're like, oh, well, chances are like, this is a 1% chance that's never going to happen

to you. And you keep kind of finding yourself there again and again and again. So getting more information, more insights up front before you keep hitting those roadblocks that, you know, your care team might be saying, like, oh, statistically, like, that's not going to happen. Right. It's really helpful. Not just from the financial cost, the emotional cost, the ability to make decisions confidently about what comes next. That doesn't usually happen in this process. You know, your provider is telling you true statistics, but if it doesn't match your experience and you're like, wait a minute, am I working with the right provider? Right. When actually,

I mean, you probably are. Right. You know, it's just, you know, your experience is different from the average experience, and nobody is exactly average. Yeah. Well, can you talk to us a little bit about cost and access? Is this being covered by insurance? Is it something that's being offered regularly in clinics? Where do we see this going in the future? Sure. So I think the most important thing to know about this from an access and coverage perspective is that choosing an embryo that's going to succeed is an area where patients and clinicians

and payers are all super aligned. Right. I think the patient part is pretty obvious that everybody wants to choose an embryo that has the best possible chance of success from a payer point of view. If you look at the specialized payers in IVF who really look at IVF statistics, who cover IVF specifically and fertility journey specifically. They all cover pgta, they all cover chromosome testing. Because if you avoid transfers that you know are likely

to fail, the whole journey is going to be less expensive and shorter. So, right. It's good for the patient and it's good for the payers. And the better we do at that decision, the better both of those groups do. And then sometimes I'll meet people and they're typically, you know, financial investors who are, you know, necessarily cynical because they're working from, you know, financial models and they think about rational behavior. So investors will sometimes ask, well, like, doesn't the doctor want their patients to have longer

journeys? Don't they want them to have more failed transfers? Don't they want them to do more failed cycles? And I mean, anybody who's talked to an REI knows that that's not true, right? That, you know, I think reis and the whole clinical teams are like massively invested in their patient success. But even if they were, you know, the most callous calculating reis, they still would want their patients to succeed as quickly as possible. And I think that the reason for that is that in a transfer cycle, that $5,000

cost, only a relatively small fraction of that is captured by the clinic. A lot of that is medication costs. So those transfer are not actually particularly profitable events for clinics. They also know that when patients have failed transfers, they leave and move to a different clinic. Most clinics have a waiting list and they have a lot of patients who want to come into the clinic. And if they can have an individual patient journey be shorter, they can serve more patients with their same staff, their same infrastructure. So even in the most cynical view of the world, this is good for clinics as well. And if you want real proof

of that, when private equity buys clinics, they actually do more pgta, not less. It's not because it's a profit center for them. It's because that equation really works at the clinic operating level that if you can see more patients with the same infrastructure, by having them succeed faster, you're running a better, more efficient, more profitable clinic. So it really is this rare area in medicine where if you make this one decision better, which embryo do we transfer? Which embryo has the best chance of success? Every single piece of this system works better. And when that works better, that means that payers can

cover more patients at the same cost. The cost of coverage goes down when the efficiency of treatment goes out. So sorry, that's a very like economicsy answer. To the question. But I think that it's important because even if you want to be super cynical about how everybody acts within the system, you can still trust that they're aligned on this decision. So when payers cover pgta, it's not because they're making money from it. It's because it's going to help you succeed faster. And the payers who do that, they don't have an age cutoff. They cover PGTA for all their patients

because every failed transfer is a longer journey and a more extensive journey. And for patients, it's a more painful journey. And for employers, it's a patient who's distracted for longer. Like everybody. Everybody. Everybody wants the journey to be as short as possible. Yeah,. Yeah,. No, that's great. That's really helpful. Sometimes you need that cynical viewpoint to frame your appeal. You know, we hear from people all the time that certain pieces of their treatment have been denied. And, you know, you would like to think that the emotional side, like, this is good for everyone would be a valid

argument, but sometimes it is the financial one that ends up moving the needle, unfortunately. Yeah. So if anybody listening now is interested in learning more or seeing if their clinic offers this testing, how do they go about it? Is it starting to be a little bit more widespread? Are you still mainly in the development stage? Can you talk about, like, what the access looks like right now for patients? Juniper testing is. Is available. You know, we're. We're currently working with over 35 rais around the country who have already, you know, worked with us with Juniper patients. Most of

the major fertility networks are able to work with us. And, you know, we really have built something with Juniper that is aligned with clinical goals. This is not a have a better baby product. Juniper is not a IQ product or a high product or even, you know, a diabetes or a complex disease product. Juniper is a. Let's understand why euploid embryos fail and avoid those failures with pgtg. It is Juniper Insight where we're looking at parent genetics

and saying, can the genetics of the parents themselves be contributing to their infertility? So we can do a blood test where we're looking at over 900 genes, where, you know, particularly if you've had, you know, a journey with a lot of failures, we're finding that there are sometimes contributions to that from the parental genomes that we can look at and help guide the next steps on your journey. So we're trying to look at every step of the IVF journey and just say, like, is there a genetic contribution here that is impacting the success of your fertility journey that we can help you identify, understand, and address. And, you know, that's something that really

resonates with clinicians and clinics. So even if you're talking to your clinician and they've never heard of us or they're not working with us yet, we're happy to have you introduce us to them. This is not something where you need to go in and, you know, bang on a table about something that is different from what they're trying to accomplish. It really is something that aligns well with what they want to do. And so we're generally very successful in those conversations. So if you're interested, you know, reach out to us on our website, junipergenomics.com, send us a note. We'll connect with you and your clinic. Those conversations

rarely pose a challenge to you on your journey, which is sometimes it takes a minute to get everybody introduced to the science and up to speed. But what we're trying to accomplish is the same as what you as a patient are trying to accomplish is the same as what your clinic is trying to accomplish for you. So we do it in a way that makes it really easy for the clinical workflow as well. So Juniper does the PGDA testing, right? So whole genome sequencing is expensive. It costs about $2,000 an embryo to do PGTG, which sounds like a lot, but compared to a $5,000 failed transfer,

unfortunately, it's not that bad. And it really makes economic sense. But also it gives you that data, and you don't have to do that testing on all your embryos. You can just do it on the chromosomally normal embryo. So we do PGT A first, and then you can do PGTG on all of your euploid embryos. You could do it on your top morphology embryos. You could do it on your male euploid embryos or your female euploid embryos. It's really, once we've done that pgta, we can come back to that and do the deep sequencing at any time. So even if you don't decide to do PGTG right away, you transfer an embryo and it fails, we have that

data, and we can come back and try to explain what happened and try to avoid it for the future embryo transfers. So being able to start with Juniper for your PDTA really leaves that door open to get that data in whatever way makes sense for you and your journey later on. And you mentioned you also do some testing with the parents sometimes can you talk a little bit more about that. Yeah, we just launched this, actually. We built this really, with Dr. Millie Thakur, who works on unexplained infertility a lot. And we found, particularly with parents who've been experiencing long infertility journeys, we saw this organically with some of

the patients we worked with who had those journeys, that about between a quarter and a half the time, there is actually something that is causing them to fail repeatedly in the parent genetics. Sometimes that's something that we can address. There was a family, the mom had genetically extremely high cholesterol that actually, to the extent that it impairs implantation. So, like a really young mom with multiple euploid transfers, no history or known history of cardiac events. We found this gene that explained it was really high cholesterol and the implantation failure. She

saw a cardiologist, got her cholesterol down prior to transfer, had a successful transfer, ongoing pregnancy. Sometimes the answer is that there's a defect in the way that eggs or sperm are made or the way that their embryos develop that is inherited from those parents. And there isn't going to be something that we can do, but it is going to say, this is the set of gametes that you need to look for a donor to, or you do need to use a surrogate. And there's a good chance it'll help because we understand what's happening here. And even when that's not the shape of the journey that parents thought that they were on, knowing

why they've been failing allows them to give themselves permission often to try a different path where they've been withholding that permission from themselves for a long time. So that data has been, like, incredibly helpful to parents in helping them understand what's going on with their journey and figure out what to do next. Yeah. I mean, it's clarity and answers so that people can make choices. Yeah. With a real understanding of what's going on. We call that Juniper insight testing. The good news about that

is you don't have to be starting a new cycle. You don't have to rebiopsy embryos. It's just a blood test on the parents that we can do at any time in your infertility journey. And I really hope, actually, that this is going to be something that people start doing earlier in their fertility journey so that you could find out maybe when you first show up in an IVF clinic, it was part of a workup. If you have something that's going to genetically prevent you from succeeding, instead of nine Years later, which is sometimes when we found these with patients, or even when you go to your OBGYN and you say, hey, I'm having trouble conceiving right now. Your OBG is doing workup that doesn't include anything

about your genetics. Maybe it should for those practitioner patients who are going to be just in for a really long hard time. That's really fascinating. Just thinking back to. That's super helpful to just get as much information as you can up front. Then you can be confident about the decisions that you're making going forward. Yeah, yeah. That's such a gift. Yeah. I mean. And you know, the other piece that is not related to pregnancy success, but the other piece, that's this gap in genetics that we've been addressing with both Insight and pgtg. And it's

related, you know, Leanne, to what you said earlier about how, you know, you assume that when you've done what's offered, that you've done everything. And people say that about carrier screening all the time. They say, oh, I'm not worried about genetic disease. I had a big carrier. Like, we're negative. Right. We did carrier testing. We're negative for everything. And the biggest carrier panels are about 800 genes, and there are over 6,000 known genetic diseases. So those other 5,200 diseases are individually super rare.

And sometimes there are things like carrier screening, by definition, does not generally address things that impact the parents themselves. They just address things between the parents that might impact future children. So you might have a genetic disease like a cardiovascular disease or cancer risk gene yourself that's not being tested intentionally in those carrier panels because they're not talking about you and your risk, even though that risk is also passed down to future kids. So when we do PGTG and we test embryos, 10 to 15% of embryos that are being transferred today have a genetic

disease in them outside of carrier screening that's not being tested. Yeah, I think that's really helpful to understand the, like, what are some of the limitations of the testings that we're currently offered today? And I think it's an important question, you know, when you're talking to your clinician or when you're talking to a genetic counselor or when you're, you know, talking to someone from a lab, you can say, you know, what is missing from this test? What don't you know, what aren't you able to tell me today? And, you know, you get a very transparent answer to that from Juniper. Right. We're not going to be able to tell you with 100% certainty, or

even, you know, yet 90 or 95% certainty that this embryo is going to succeed or fail. But we're going to be able to give you a lot more information than is available today. We're going to give you a much better chance of success than is available today without this technology. But there are limitations to it. There's things we can't detect, there are single gene disorders that we can't detect. So every lab has its limitations, every test has its limitations, and I think you want to be able to understand those, understand what you're missing and make an informed decision about that. And with Juniper, we've just found these gaps that are really important to people, that are not being addressed in terms of embryo

success and genetic disease that we're trying to offer to people much sooner in their journey than they're finding out about them today. That's great. That sort of leads into another question, which is, what are you most excited about in reproductive technology? Where do you think this is going? And. Yeah, what gets you excited? Yeah, I'm really excited. I mean, obviously I'm really excited about what we're building at Juniper. I'm excited for more and more people to have access to this, more and more people to succeed sooner in their journeys and understand what's going on with their infertility journey much sooner than they're able to today. I'm also really excited for what we can build. We've started

with reduced viability variants and disease variants that are part of a really solid foundation of genetic understanding that we have today. And what's the gap between there and that? 95 to 98% of people who we know will succeed with the sufficient number of transfers. How do we get from where we are today? We're presenting some early outcomes data at ASRM this year that's showing that we're way ahead of where we are with PGTA alone, but we're not at that 95 to 98% level yet. So what are the other things that explain that gap? How do we at Juniper use the research that

we're doing? The data that we're collecting on not just the genome of the embryo, but the rna, the transcriptome of the embryo that we collect from every embryo. How can we understand that data better? And so each step that we take towards that understanding, I think is going to be a step towards what we hope is ultimately a very, very high confidence in the first transfer. So I'm really excited about that. It is by far the most gratifying, meaningful, exciting science that I've ever had a chance to be involved in across my career. And then there's, you know, there's a bunch

of other cool science that's being done. IVF right now. You know, there's, there's fascinating work that's being done on being able to develop gametes from stem cells, you know, so that same sex couples or, you know, couples who don't have functioning gametes might be able to have their own biologically related kids. There's fascinating work being done. There's a company called Euploid in Europe that's working on medications that might help more chromosomes segregate accurately so that you have more Euploid embryos to begin with. There's Evie that's doing fascinating

work on the vaginal microbiome and the relationship between the microbiome and pregnancy outcomes and infertility outcomes and success. There's a ton of exciting science. I love going to meetings in this field because everybody is just so incredibly motivated and dedicated to finding more answers for patients and helping make that journey faster and easier. An area that it's easy to feel very passionate about. So it's exciting to think about what's coming next. The technology and our understanding just changes so quickly.

Yeah. And it's overdue. We say, juniper, it's about time because it's about the time that your journey takes. But it's also success rates in IVF have been the same for over a decade and that's too long. Yeah, agree. So much to be excited about right now. Yeah. Well, thanks. I mean, thanks so much for this and thanks for the work that you're doing helping people find their paths through this journey. It's, it's so challenging and emotionally fraught. And I think it's what makes it so meaningful to be able to talk

about and contribute to. Thank you. As we wrap up, there are a couple questions that we like to ask all of our guests and we'd love to get your perspective on these. The first is what is one thing that you would say to somebody who is just starting to try to grow their family? I would say this is a two sided equation, right? There is an egg source and there is a sperm source. And there's so much conversation about how female fertility declines with age. But guess what? 45 year old dads contribute twice as much genetic

risk to their embryos as 25 year old dads. So if you're thinking about freezing your eggs, like, how much easier and cheaper is it? For your male friends to freeze their sperm. Firm, like, vastly easier and cheaper. But never talked about. Ever. But never talked about, in part because we haven't been measuring it. Right. Female infertility shows up as chromosome abnormalities, which are very easy to measure. And male contributions show up as individual typos, which are very hard to measure. Right. But as we measure them, guess what? They're there. They're contributing

to risk, they're contributing to disease risk, they're contributing to infertility risk. And it goes up with male age as well. So I think that's the one thing I would say is just get your male partners, get your male friends involved in this conversation. It is sometimes embarrassing as a male to see how little the male partners are contributing to an infertility journey. But aside from the emotional labor and the challenge of going through this process, there are concrete things that men can do to get know, improve their

sperm health, to preserve their fertility themselves, like get on it. I love that. I love it. How can someone show up for a friend or family member who is struggling to build their family? Yeah, I was thinking about this. I mean, I think that's a very individual question, both for the person going through the journey and for the people showing up. So probably the most important way to show up is just to be present and to ask. And for me, it's

my bias, but I think you can show up with data. It's hard to know everything, and it's hard to think about everything. And so I think the opportunities I've had to say to people, and through Juniper, the unbelievable privilege of being able to say to people, hey, here's an explanation for what you've been experiencing. Here is a next step that might help you figure out how to succeed on this journey is, you know, is such an incredible privilege. And I think we have a unique way of doing it at Juniper, but I think that that's a way that anybody could show up, that

maybe they're not thinking about showing up today is, you know, do some research, show up with data. Take whatever expertise you have and try to apply it to help your friends who are going through a challenging time. Right. Love that. Thank you. Yeah. Where it's invited. Right. Where it's. The asking is definitely, like, the critical part of that. I will. As someone who sometimes shows up with unsolicited information, like data. Data. Not everybody, you know, wants that

at every moment of every income of their lives. But, yeah, both of those things. I mean, I would find that helpful. That's just my. Well, thanks Jeremy. It's been so wonderful talking with you today. We'll put your links in the show notes so anybody listening can get in touch. Thanks. Yeah, of course. This has been a really lovely conversation. It's been great to learn more about the work that you're doing. It's so cool and so exciting and it's going to help so many people. So thank you for doing the deep dive and changing outcomes for so many folks out there.

Thank you so much for having me for the opportunity to talk about it today. Thank you for listening. We'll see you next week with more family building stories and resources. Be sure to subscribe wherever you listen to podcasts so that you never miss an episode and follow us on social media at AllPathsFB or visit our website, AllPathsFB.org to learn more about our work. And please help spread the word so that anyone who is struggling to grow their family can

join the conversation. Allpaths Family Building is so grateful to the members of our circle of support today. We'd like to recognize and thank First Fertility. Your partnership is vital to our ability to provide emotional support, support, education and advocacy that is open to anyone who is struggling to grow their family and to the entire All Paths community. Thank you for being here. It's an honor to walk with you on your journey.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. "I Was Meant to Be a Mother to Whoever Came to Me, However They Came"

    Nov 17, 202642 minAudio

    What happens when your path to parenthood looks nothing like you planned, and how do adoption, miscarriage, and surrogacy reshape our definition of family? In this episode of the AllPaths Podcast, we explore this...

    Credit the people on this episode

  2. Lyla's Legacy

    Nov 10, 20261 hr 1 minAudio

    In this episode of the AllPaths podcast, we sit down with Heather Toland for an honest conversation about loss, resilience, and the complexities of growing a family. Heather shares the heartbreaking story of her...

    Credit the people on this episode

  3. "It’s Okay That It Sucks"

    Oct 27, 20261 hr 2 minAudio

    After enduring four pregnancy losses in just twelve months, the most healing words Macie heard didn’t offer false hope or easy silver linings, they simply acknowledged the brutal truth: "it's not ok, this sucks." In...

    Credit the people on this episode

  4. Unexplained Is Unacceptable

    Oct 20, 202642 minAudio

    Driven by the stark reality that half of all recurrent pregnancy loss cases go completely unexplained, Recurrent Pregnancy Loss Association (RPLA) co-founder Megan Hanson shares her story and discusses turning patient...

    Credit the people on this episode

  5. "Two Things Can Be True at the Same Time"

    Oct 13, 202649 minAudio

    How do you hold space for others through infertility, pregnancy, and the postpartum period while quietly navigating your own recurrent pregnancy loss? In this episode of the AllPaths podcast, we sit down with Caitlin...

    Credit the people on this episode